Doctor N.E. Chernobayev
+7 (921) 657-60-44
: 0
to the amount of: 0 руб.
Proceed to checkout
Ask a question

Clinical studies

Clinical studies       

October, 1997


By now, urologist in many countries have started to treat BPH with b1-adrenoblockers (Tamsulosin, Alfuzosin and Terazosin), which block b1-adrenoreceptors of bladder cervix and the prostatic segment of urethra. In this way, it is possible to eliminate or educe the dynamic component of obstruction and to restore coordination in the operation of detrusor and the sphincter apparatus of bladder and thus to contribute to normalization of urination acts [4]. However, this is not associated with a decrease in prostate size [9]. Long-life treatment with b-adrenoblockers is advised.

The use of 5a-reductase blockers (Proscar, Finasteride, MSD etc.) is based on the blockage of testosterone conversion to dehydrotestosterone. To achieve a symptomatic improvement, the drugs should be administered for not less than one year. In the group treated with Finasteride, an increase in the maximal urination velocity by 32.5% was noticed. The L-PSS index and prostate size decreased, on average,  20% and 32%, respectively [5] (see Table 1) .

Table 1. Comparative changes in Qmax and prostate volume in BPH patients treated using different therapies


Treatment duration

Increase in Qmax (%)

Decrease in prostate size (%)

Changes in symptoms (%)

Alfuzosin (Perepanova, 1977) [6]

84 days


No changews


Finasteride (Loran, 1977 [5]

1 year





2-3 months




The above drugs have side effects. For example, b1-adrenoblockers cause orthostatic responses, vertigo, headache, fatigue, feeling bad, edemas, sleepiness, nausea, vomiting, and retrograde ejaculation

The moist significant side effects of 5a-reductase include impotence, decreased libido, and decreased ejaculate volume.

The indication for treating of BPH patients were clinical manifestation according to patients' complaints (score 20 by the J-PSS scale). The patients were examined before treatment and 2-3 months thereafter. The following parameters were used to assess treatment results:

  • clinical manifestations by the J-PSS scale;
  • quality of life index (L)
  • urofluorimetric index;
  • prostate size;
  • residual urine volume in stage II patients

Over the last 4 years, the method presented herein was used to treat 203 patients aged 61 to 76 years, including 186 Stage I patients and 17 Stage II patients. After 3 months of the treatment, the total score by the J-PSS scale decreased by 21.2 (from 25.9 to 4.7), i.e., by 82%; the quality of life index "L" changed by 3.35 =60.9%), i.e., from 5.5 to 1.7; and the urofluorimetric index Qmax increased from 7.4 mL/sec to 13.2 mL/sec, i./e., by 5.89 mL/sec (43.9%). Prostate size decreased by 24.8 cm3 on average (according to ultrasonography), which makes 35-40% of the initial volume (see photo). The mean residual urine volume decreased by 134.5 cm3 (from 149 to 15.2 cm3). Long-term results for up to 4 years of treatment are available. The results are good.

The therapy under discussion was successfully used to treat chronic prostatitis. The conventional methods of treatment of prostatitis are usually ineffective. One of the reasons of this low effectiveness is the insufficient penetration of the drugs into the prostate. ECADO as a monotherapy was used to treat 363 patients aged 20 to 51 years. The criterion of the quality of the treatment were patients' complaints, prostate secretion  normalization, crystallization phenomenon, palpation and ultrasonography results, and the results of bacteriological inoculations of the third portion of urine and of prostate secretion. The patients of this group received the treatment for about 2 months. The results proved to be good.

ECADO was found to be highly effective in treatment of patients having an impaired copulative function. The beneficial effects were manifested as the restoration of full-blown erection and coitus duration in 256 out of 271 patients. The age of the patients ranged from 18 to 74 years (see Table 2).

Table 2. Comparative effects of  Viagra and ECADO on the copulative function



The principle of action

"+" (1)

"+" (2)

Relaxation of smooth muscles of peripheral arteries and cavernous bodies


"+" (3)

Tone up the venous vessels Pl. paravesikalis


"+" (4)

Influence on the ejaculatory component of the copulative cycle


"+" (5)

Activation of the sacral segment of the parasympathetic nervous system (even under spinal shock conditions)

(1)     It is possible that cyclic guanosine 3,5-monophosphate (cGMP) serves as the intracellular mediator (second messenger). Cholinomimetics reduce cGMP in blood plasma and many tissues. Viagra inhibits the enzyme phosphodiesterase, which in its turn cleave cGMP.

(2)     This occurs by the M- and N-cholinolytic action in a synergism with the M-cholinomimetic action of the endogenous acetylcholine and, also, by the N-cholinolytic action in the sympathetic ganglia (anticholinergic and antiadrenergic effects).

(3)     Toning up of the venous vessels occurs by the direct action on the chemoreceptors of the venous wall.

(4)     This occurs by blocking of N-cholinoceptors in the sympathetic ganglia of ejaculation center of the sympathetic nervous system (L1-3).

(5)     This occurs in the sacral segment S2-4 of the parasympathetic nervous system where the erection center is located.

Good results are also obtained in the treatment of stage II-III oligoastenozoospermia. The causes of and specific therapies for most cases of sperm pathology and male infertility are still unknown. About one half of all male infertility cases are idiopathic. Several empirical therapies are known, each one having its proponents. However, none is scientifically substantiated and provides for what is usually required to assess the efficiency of a given drug. The method in consideration was used as a monotherapy to treat 28 patients. Spermogram normalization in 24 patients occurred in 2.5 to 4 months. Four patients were unresponsive.

The preparation ECADO, whose effectiveness is well proved, has the following pharmacological properties:

  • plays the role of protective colloid with regard to the biocolloids of prostate secretion and stromal tissue;
  • possesses M- and N-cholinolytic effects;


Thus, the use of the present therapy will provide for the following:

  • expansion of the range of preparations used to treat patients suffering from BPH, prostatitis, infertility, and impotence;
  • possibility to use the preparation for preventive purposes; and
  • possibility to use the preparation during prelude to planned adenectomy

The ultrasonogram shows the dynamics of changes in prostate size in patient G, born in 1926, diagnosed with I stage prostate adenoma.

Rambler's Top100
Clinical studies